Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Research & Development (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Research & Development data on record, last reported at $10.8 million in Q1 2026.

  • On a quarterly basis, Research & Development rose 3.1% to $10.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $30.1 million, a 20.61% increase, with the full-year FY2025 number at $29.8 million, up 73.11% from a year prior.
  • Research & Development reached $10.8 million in Q1 2026 per IKT's latest filing, up from $6.4 million in the prior quarter.
  • Over the last five years, Research & Development for IKT hit a ceiling of $13.6 million in Q4 2023 and a floor of $2.8 million in Q1 2024.
  • A 5-year average of $5.5 million and a median of $4.2 million in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 344.91% in 2023, then plummeted 47.06% in 2024.
  • Tracing IKT's Research & Development over 5 years: stood at $3.1 million in 2022, then soared by 344.91% to $13.6 million in 2023, then tumbled by 47.06% to $7.2 million in 2024, then decreased by 11.6% to $6.4 million in 2025, then surged by 70.46% to $10.8 million in 2026.
  • Business Quant data shows Research & Development for IKT at $10.8 million in Q1 2026, $6.4 million in Q4 2025, and $7.6 million in Q3 2025.